Last reviewed · How we verify

NCT06344572

Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia

Recruiting now NA Last updated 13 August 2025
What this trial tests

NA trial testing SAT-001 in Myopia in 110 participants. Currently enrolling.

Timeline
27 September 2023
Primary endpoint
31 August 2025
30 September 2025

Quick facts

Lead sponsorS-Alpha Therapeutics, Inc.
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment110
Start date27 September 2023
Primary completion31 August 2025
Estimated completion30 September 2025
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

S-Alpha Therapeutics, Inc.

Who can join

Adults 5 to 8, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this clinical investigation is to evaluate the efficacy and safety of SAT-001 designed as Software as Medical Device (SaMD) for slowing myopia progression and treatment in pediatric myopia patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Digital therapeutics approach for young children with myopia using SAT-001 (DAYS): study protocol for a randomized controlled trial.
    Paik HJ, Lee BJ, Lim DH, Han SY, et al · · 2025 · PMID 40200346 · DOI 10.1186/s13063-025-08717-w

Verify or expand the search:

Other trials of SAT-001

Trials testing the same drug.

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other S-Alpha Therapeutics, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06344572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing